Experimentally induced liver tumors in mice harbor activating mutations in either Catnb (-catenin) or Ha-ras, according to the carcinogenic treatment. We have now investigated by microarray analysis the gene expression profiles in tumors of the two genotypes. In total, 364 genes or expressed sequences with aberrant expression relative to normal liver were identified, but only 30 of these demonstrated unidirectional changes in both tumor types. Several functional clusters were identified that involve changes in amino acid utilization and ammonia disposition in Catnb-mutated tumors as opposed to alterations in lipid and cholesterol metabolism in Ha-ras-mutated tumors. Moreover, several genes coding for inhibitory molecules within the Wnt-signaling pathway were upregulated in Catnb-mutated tumors, suggesting induction of a negative feedback loop, whereas Ha-ras-mutated tumors showed alterations in the expression of several genes functional in monomeric G-protein signaling. We conclude that mouse hepatoma cells adopt different evolutionary strategies that allow for their selective outgrowth under variable environmental conditions. Human hepatocellular cancers (HCC) lack RAS mutations but are frequently mutated in CTNNB1, the human Catnb ortholog. The set of genes aberrantly expressed in Catnb-mutated mouse tumors was used to screen, by expression profiling, for dysregulation of orthologous genes within a panel of 25 HCCs, of which 10 were CTNNB1-mutated. HCCs with activated -catenin displayed a gene expression profile that was similar to Catnb-mutated mouse tumors but distinct from the other human HCCs. In conclusion, expression fingerprints may be used for diagnostic purposes and potential new therapeutic intervention strategies. Supplementary material for this article can be found on the HEPATOLOGY website (http://www.interscience.wiley.com/ jpages/0270-9139/suppmat/index/html). (HEPATOLOGY 2005;42:353-361.) R odent hepatocarcinogenesis is a powerful experimental system to analyze genetic changes relevant for tumor formation in the liver. Mouse liver tumors induced by a single injection of a liver carcinogen such as N-nitrosodiethylamine (DEN) frequently harbor activating mutations in the Ha-ras proto-oncogene. 1,2 If, however, DEN treatment is combined with subsequent chronic administration of the liver tumor promoter phenobarbital (PB) according to a classical initiation-promotion protocol, tumors predominate that lack ras mutations but show activating mutations in the Catnb (-catenin) proto-oncogene instead. On histological examination, liver tumors generated in the absence or presence of the tumor promoter PB demonstrate considerable differences in hematoxylin-eosin-stained sections: the former are often basophilic and are generally composed of comparatively small cells, whereas the latter are often eosinophilic and contain larger cells with enlarged nuclei. 4,5 Several additional differences have been described if individual markers were used for discrimination of tumor types including glutamine synthetase (GS), which is strongly increased in expression in Catnb-mutated but undetectable in ras-mutated mouse hepatocytes. This suggests that mutation in either of the two genes produces divergent phenotypes; however, comparative genome-Abbreviations: DEN, N-nitrosodiethylamine; PB, phenobarbital; GS/glul, glutamine synthetase (protein/gene); HCC, hepatocellular carcinoma; PCR, polymerase chain reaction; HCV, hepatitis C virus; CAR, constitutive androstane receptor.